Market Alert: Trump Revives Trade War Playbook with Tariff Threats
Opyl Limited (ASX: OPL) has received firm commitments to raise AU$ 1.5 million through a strategic placement to accelerate the development and commercial expansion of its AI-powered drug discovery and clinical trial design platform, TrialKey. The heavily oversubscribed placement reflects strong investor confidence in TrialKey’s global potential and Opyl’s mission to enhance trial design with more innovative, faster AI-driven solutions.
The raise will fund TrialKey’s sales, marketing, infrastructure, ongoing development, and general working capital. Director Antanas Guoga (Tony G) participated in the placement, further endorsing the platform’s growth trajectory. The placement involves the issue of approximately 71.43 million shares at AU$0.021 per share—a 19.2% discount to the last close and a 23.4% discount to the 15-day VWAP—along with one free attaching option (exercise price AU$0.03, 4-year expiry) for every two shares.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
